CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 17 enrolled
Drug / intervention
Levetiracetamdrug
Likely dose
Levetiracetam 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00265109
NCT00265109Phase 4Completed
CompareCT.gov

Open-Label Study of Levetiracetam in Body Dysmorphic Disorder

Butler Hospital·interventional·Posted Dec 14, 2005·Updated Aug 29, 2019

In Brief

A Phase 4 clinical trial evaluating Levetiracetam for Body Dysmorphic Disorder. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the usefulness of a medication (Levetiracetam) for people with body dysmorphic disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBody Dysmorphic Disorder
CountriesUnited States
CollaboratorsUCB Pharma

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 14, 2005
Enrollment StartDec 1, 2004
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 20.6 years ago

Interventions

Levetiracetamdrug

The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.